An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment.

Trial Profile

An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity
  • Focus Pharmacokinetics
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 29 Mar 2017 Results assessing pharmacokinetics and tolerability of Lorcaserin in different populations in three studies (NCT00828581, NCT00828438, and NCT00828932) published in the Clinical Therapeutics
    • 30 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jul 2009 Actual initiation date changed from Sep 2008 to Aug 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top